Zanubrutinib
- Generic Name
- Zanubrutinib
- Brand Names
- Brukinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O3
- CAS Number
- 1691249-45-2
- Unique Ingredient Identifier
- AG9MHG098Z
- Background
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
- Indication
Zanubrutinib is indicated for the treatment of:
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
- Associated Therapies
- -
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT02914938
- Locations
- 🇺🇸
Swedish Cancer Institute, Issaquah, Washington, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Compassionate Care, Corona, California, United States
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 75
- Registration Number
- NCT02795182
- Locations
- 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 119
- Registration Number
- NCT02569476
- Locations
- 🇺🇸
Florida Cancer Specialists Fort Myers, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 385
- Registration Number
- NCT02343120
- Locations
- 🇦🇺
St George Hospital, Sydney, New South Wales, Australia
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺Peter MacCallum Cancer Centre, East Melbourne, Parkville, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.